Although anti-CTLA-4 treatment has been shown to trigger or worsen severity of autoimmune diseases in experimental models, a similar effect has not been shown for PD-1/PD-L1 abrogation [2–4]. The gene discussed is CTLA4; the disease is autoimmune disease.